Evidence map›Paper›PMID 42138139›Full record

ArticleThe Journal of infectious diseases2026

Infants Younger Than 24 Months With Severe Malaria Have a Serologic Profile of Active Infection With Epstein-Barr Virus.

Wayne T Cheng, Balotin Fogang, Aarti Jain, D Huw Davies, Philip L Felgner, Carole Eboumbou, Paul N Koki, Samuel H Speck, Chester J Joyner, Lawrence S Ayong and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Wayne T ChengDepartment of Infectious Diseases, College of Veterinary Medicine.
Balotin FogangMolecular Parasitology Laboratory, Centre Pasteur du Cameroun, Yaoundé, Cameroon.
Aarti JainVaccine Research and Development Center, Department of Physiology and Biophysics, University of California, Irvine.
D Huw DaviesVaccine Research and Development Center, Department of Physiology and Biophysics, University of California, Irvine.
Philip L FelgnerVaccine Research and Development Center, Department of Physiology and Biophysics, University of California, Irvine.
Carole EboumbouFaculty of Medicine and Pharmaceutical Sciences, University of Douala.
Paul N KokiMother and Child Centre of the Chantal Biya Foundation, Pediatric Service, Yaoundé.
Samuel H SpeckDepartment of Microbiology and Immunology, Emory University School of Medicine and the Emory Vaccine Center, Emory University, Atlanta, Georgia.
Chester J JoynerDepartment of Infectious Diseases, College of Veterinary Medicine.ORCID 0000-0003-1367-2829
Lawrence S AyongMolecular Parasitology Laboratory, Centre Pasteur du Cameroun, Yaoundé, Cameroon.
Tracey J LambDepartment of Pathology, University of Utah, Salt Lake City, USA.ORCID 0000-0003-0620-3944

Funding

Systems Biological Analysis of Innate and Adaptive Responses to VaccinationU19AI090023 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, LI, SHUZHAO · 2010 to 2021
$45.0M
Suppression of anti-malarial humoral immune responses by gamaherpesvirusesR01AI123425 · NIAID · UNIVERSITY OF UTAH · PI LAMB, TRACEY JANE · 2017 to 2021
$1.9M
National Institute of Allergy and Infectious Diseases 1R01AI123425NIAID NIH HHS R01 AI123425NIAID NIH HHS U19 AI090023NIH
6 · The paper itself

Abstract

backgroundPrimary Epstein-Barr virus (EBV) infection occurs during late adolescence and is characterized by the symptomatic manifestation of infectious mononucleosis. Asymptomatic primary EBV infection in malaria-endemic areas often occurs in young children by the age of 2 years. Resulting in humoral immune suppression to unrelated antigenic challenges for approximately 4 weeks.

methodsWe undertook a cross-sectional study of 195 infants aged 6 to 24 months in Cameroon. The EBV infection status of each child was determined by a standard serologic classification system, and the magnitude, breadth, and invasion-blocking capacity of the anti-Plasmodium falciparum antibody response were quantified.

resultsAn overall 24% of children were serologically positive for active EBV infection, and the highest proportion of severe malaria cases was in children with active EBV. An elevated magnitude and breadth of the antibody response with increased in vitro invasion-blocking capacity were observed in children with active EBV, but circulating parasitemia in vivo was similar.

conclusionsPrimary EBV infection may be a risk factor for developing severe malaria in children aged 6 to 24 months. Targeting EBV infection in young children may be beneficial in protecting against the development of severe falciparum malaria in children living in malaria-endemic areas.

Indexed as

Epstein-Barr Virus InfectionsHerpesvirus 4, HumanMalaria, FalciparumAntibodies, ProtozoanAntibodies, ViralCameroonChild, PreschoolCross-Sectional StudiesFemaleHumansInfantMalePlasmodium falciparumAntibodies, ProtozoanAntibodies, ViralcoinfectionEBVhumoral responseP falciparumprotein microarray

Identifiers

PMID42138139
PMCPMC13600389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.